Tesofensine
Chemical compound
Tesofensine (NS2330) is a serotonin–norepinephrine–dopamine reuptake inhibitor from the phenyltropane family of drugs, which is being developed for the treatment of obesity. Tesofensine was originally developed by a Danish biotechnology company, NeuroSearch, who transferred the rights to Saniona in 2014.
Nº Q7705544 ★
Común · Saberes
Tesofensine
Chemical compound
Tesofensine (NS2330) is a serotonin–norepinephrine–dopamine reuptake inhibitor from the phenyltropane family of drugs, which is being developed for the treatment of obesity. Tesofensine was originally developed by a Danish biotechnology company, NeuroSearch, who transferred the rights to Saniona in 2014.
Último precio
—
Precio mínimo
—
Mediana 7 d
—
Ventas 30 d
0
Rango 30 d
—
En circulación
0
Cotización
mediana
mín – máx
ventas
Sin ventas en el periodo
Ver tabla
| Fecha | mediana | Mín | Máx | ventas |
|---|
Historial de ventas
- Última venta
- —
- Media 30 d
- —
- Mínimo 30 d
- —
- Máximo 30 d
- —
- Ventas 7 d
- 0
- Ventas 30 d
- 0
Aún no hay ventas.
Ventas anónimas: sin comprador ni vendedor. Las cifras solo cuentan ventas entre jugadores.
En Wikipedia
Texto en inglés Aún no hay artículo en tu idioma: extracto en inglés.
Tesofensine (NS2330) is a serotonin–norepinephrine–dopamine reuptake inhibitor from the phenyltropane family of drugs, which is being developed for the treatment of obesity. Tesofensine was originally developed by a Danish biotechnology company, NeuroSearch, who transferred the rights to Saniona in 2014. As of 2019, tesofensine has been discontinued for the treatment of Alzheimer's and Parkinson's disease but is in phase III clinical trial for obesity.
Texto: Wikipedia en inglés, CC BY-SA 4.0. · Imagen: Cacycle (Public domain) ·
